Tocilizumab
- Generic Name
- Tocilizumab
- Brand Names
- Actemra, RoActemra, Tyenne, Tofidence
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 375823-41-9
- Unique Ingredient Identifier
- I031V2H011
- Background
Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflamm...
- Indication
Tocilizumab is indicated to treat moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.
...
- Associated Conditions
- Coronavirus Disease 2019 (COVID‑19), Cytokine Release Syndrome caused by CAR-T Cell Therapy, Giant Cell Arteritis (GCA), Juvenile Chronic Polyarthritis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis (SJIA), Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), Active systemic Juvenile idiopathic arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- Monotherapy
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 3
- Registration Number
- NCT05769959
- Locations
- 🇺🇸
SCRI Oncology Partners, Nashville, Tennessee, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics
- Conditions
- Interventions
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT05730777
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT05646836
- Locations
- 🇬🇷
University of Athens, Hematological Clinic,; First Department of Propaedeutic Medicine, Athens, Greece
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
Tocilizumab for Acute Chest Syndrome
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 200
- Registration Number
- NCT05640271
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
- Conditions
- Interventions
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 168
- Registration Number
- NCT05619744
- Locations
- 🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
- Conditions
- Interventions
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 90
- Registration Number
- NCT05609630
- Locations
- 🇯🇵
Institute of Science Tokyo Hospital /ID# 251505, Bunkyo-ku, Tokyo, Japan
🇸🇪Queen Silvia Children's Hosp /ID# 251318, Gothenburg, Vastra Gotalands Lan, Sweden
🇺🇸New York Medical College /ID# 253437, Valhalla, New York, United States
Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome(SFTS)
- First Posted Date
- 2022-11-03
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Qin Ning
- Target Recruit Count
- 350
- Registration Number
- NCT05604859
- Locations
- 🇨🇳
Guangshui First Peoples Hospital, Guangshui, Hubei, China
🇨🇳Huanggang Central Hospital, Huanggang, Hubei, China
🇨🇳Luotian County Peoples Hospital, Huanggang, Hubei, China
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT05583617
- Locations
- 🇫🇷
IGR, Villejuif, France
🇦🇺Prince of Wales Hospital; Haematology, Randwick, New South Wales, Australia
🇦🇺St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 90
- Registration Number
- NCT05535244
- Locations
- 🇺🇸
Mayo Clinic - Arizona, Phoenix, Arizona, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
🇺🇸Mayo Clinic-Jacksonville, Jacksonville, Florida, United States
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 65
- Registration Number
- NCT05533775
- Locations
- 🇧🇷
Hospital Erasto Gaertner, Curitiba, Brazil
🇧🇷GRAACC - Grupo de Apoio ao Adolescente e a Crianca com Cancer, Sao Paulo, Brazil
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.